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Introduction 
 
Cardiomyopathies, arrhythmic syndromes, aortopathies, and other cardiovascular diseases with 
Mendelian inheritance are relatively frequent conditions for which genetic testing is 
recommended in various guidelines.1,2 The most widely recognized indication for genetic 
testing in patients with these conditions is to identify a causative mutation and subsequently 
provide pre-symptomatic or predictive testing of relatives who are at risk of developing the 
same disease at a later stage. This process of cascade screening of family members ensures 
adequate clinical surveillance of mutation carriers and allows non-carriers to be discharged 
from clinical follow-up. A number of studies have reported a greater cost-effectiveness 
combining molecular screening with clinical screening compared with isolated clinical 
investigations.3 
 
Previously, genetic testing was based on conventional techniques like Sanger sequencing 
analysing genes one by one, but recent advances in DNA sequencing technologies have made 
it possible to investigate large numbers of disease genes simultaneously, making mutation 
analysis much faster and cheaper. These new methods are known as next-generation 
sequencing (NGS) and represent a major advance in the ability to identify causative mutations 
in families affected by genetic diseases (see Supplementary material online, Figure S1).4,5 
However, analysis of large numbers of genes may identify a number of sequence variants of 
uncertain clinical significance (VUS). As a result, cardiologists and clinical geneticists who 
counsel and manage families with inherited cardiovascular disorders are facing a major 
challenge in determining the clinical relevance of NGS results.6,7 
 
This paper gives a brief overview of the principles of NGS, discusses the general strategies for 
the interpretation of sequencing results, and reviews the implications of NGS for cardio-genetic 
services. In addition, issues related to genetic counselling and ethical considerations are 
discussed. A summary of viewpoints is given in Table 1. 
 
 
Methods for identification of disease-causing mutations 
 
Until recently, mutation analysis has been performed mostly using Sanger sequencing in which 
the order of nucleotides in the coding sequences of a gene (exons) is analysed in series one 
after the other. The method is accurate and reproducible but also labour intensive and 
expensive, which has limited testing to analyses of relatively few disease genes. 
 
NGS uses a highly parallelized sequencing process, which makes it possible to investigate large 
numbers of genes simultaneously at greater speed and at lower cost than by Sanger sequencing 
(see Supplementary material online, Figure S1).4,5 The method is particularly useful in the 
context of hereditary cardiovascular conditions, since the number of underlying disease genes 
and causative mutations is significant for most of the disorders. In addition, the size of some 
of the disease genes—most notably Titin (TTN) and the Ryanodine Receptor (RyR2)—
impedes the use of Sanger sequencing as an analysis tool in clinical practice. 
 
NGS technology can be used in different ways. Many diagnostic laboratories offer ‘targeted 
gene panels’, in which there is a focus on a set of genes known to be associated with specific 
disorders. Others provide whole exome sequencing (WES) which covers almost all protein-
coding sequences or whole-genome sequencing (WGS) that includes nearly all non-coding 
sequences as well. 
 
Targeted gene panels have been shown to generate results with analytical quality identical to 
Sanger sequencing and have the advantage of being faster and cheaper with a better coverage 
and sensitivity than WES and WGS.4 Although WES and WGS make it possible to perform an 
unbiased search for mutations in all human genes, this approach is currently considered less 
appropriate for routine diagnostic purposes as not every part of the coding sequence is 
sufficiently covered, which may lead to false-negative results. In addition, issues related to 
management of the huge amount of data generated by WES and WGS remain to be solved 
before these approaches are suitable for routine use in a clinical setting.8,9 
Interpretation of sequencing results 
 
With the introduction of NGS into clinical practice, the number and size of genes investigated 
have increased dramatically. Since the number of variants identified by NGS is almost 
proportional to the total number of DNA bases sequenced, many more variants are being 
identified and need to be classified as pathogenic, benign, or VUS.10,11 In order to make such 
distinctions, a rigorous process of interpretation is necessary to avoid misclassification and 
thereby ensure correct counselling. This relies on a number of complementary investigations. 
 
Frequency of variants in healthy controls 
 
Several public databases provide information about the frequency of variants within the coding 
sequence of the human genome based on WES and WGS of thousands of apparently healthy 
controls. Once a sequence variant has been identified in a patient, it is important to determine 
whether it is present or absent in such databases. A high-frequency among controls indicates 
that the variant identified is likely to represent normal variation while a very low frequency or 
complete absence suggests a potential disease-associated mutation. 
 
 
Published data 
 
It is important to clarify whether the variant has already been reported as disease causing. 
However, the evidence for causation needs careful evaluation since much of the published data 
that were generated in the pre-NGS era involved a limited number of controls. It has become 
evident following the introduction of NGS that a significant number of rare variants previously 
reported to be pathogenic are in fact likely to be benign due to their presence in the general 
population.12 
 
Co-segregation in families 
 
Co-segregation of a variant with the condition in a large family with many affected individuals 
usually provides strong evidence for causation. However, families with multiple affected 
individuals is a rare occurrence and the most common clinical scenario is that of a novel 
sequence variant in an individual with only few or no other clinically affected relatives. 
Consequently, many novel variants identified by NGS will be classified as VUS and thereby 
represent an inconclusive test result at present. 
 
Likely effect on the transcribed protein and evolutionary conservation 
 
Sequence variants exert different effects on protein structure that may or may not be 
pathogenic. The probable impact on protein function can be estimated from the type of 
mutation (nonsense, missense, splice site), the level of conservation through evolution by 
comparison to DNA-sequences of other species, and by using in silico prediction tools. These 
analyses provide information about the likelihood of pathogenicity, but cannot be used in 
isolation to classify a sequence variant as relevant for clinical decision-making or genetic 
counselling. 
 
Informed consent and ethical considerations 
 
The ability to sequence all of the human genome and the consequent identification of many 
VUS presents new challenges for the counselling of individuals before and after genetic testing. 
Particular issues to consider are the possibility of reclassification of genetic variants from 
benign to disease causing (or vice versa) at a later date due to the generation of new data. In 
addition, unsolicited findings in other genes such as recognized cancer genes are reported in 
1–3% of patients undergoing WES or WGS.10 It is therefore essential to discuss with patients 
prior to WES or WGS whether genes unrelated to their condition should be interpreted and 
whether they would like to be informed about potentially relevant findings in genes unrelated 
to the condition for which they are being tested. Findings in such ‘actionable genes’ may 
potentially influence the future health condition of the patient and their family and thereby 
indicate regular follow-up to ensure timely treatment and genetic counselling. 
 
The ethical concerns about incidental findings and the current technical limitations of NGS 
with respect to gene coverage mean that, for the present, WES and WGS are considered to be 
a diagnostic method in development.8 We suggest that only recognized disease genes with 
substantial evidence of causality should be investigated when offering routine genetic testing. 
Other genes with less evidence of causality should be classified as candidate genes and 
primarily investigated for research purposes. 
Sharing information in public databases 
 
To take the full advantage of NGS, it is important to develop dedicated databases that combine 
sequencing data and clinical information about patients in order to share, compare, and 
continuously update knowledge for medical use. This will facilitate correct interpretation of 
identified sequence variants, ensure clinical efficiency, and maintain on-going evaluation of 
reported sequencing data.13 
 
In contrast, if this information is not shared, there is a considerable risk of misinterpretation of 
the impact of the variants identified, which may lead to wrongful counselling of affected 
families. 
Complexities in diagnosis and organisation of cardio-genetic services 
 
The development of NGS has not only made it feasible to offer genetic testing in large numbers 
of genes and to more patients when compared with previous methods, but it has also accelerated 
the pace of new disease gene discovery. The result is an ever growing list of candidate genes 
in screening protocols and greater complexity in the interpretation of genetic variants both of 
which make it necessary to develop continuing education of molecular biologists in 
bioinformatics and clinicians caring for patients with hereditary cardiovascular conditions. 
 
The increased availability and ever decreasing cost of NGS make it tempting to apply less 
stringent indications for genetic testing. However, it is well established that the diagnostic yield 
of genetic investigations is highest in patients with familial disease who fulfil diagnostic criteria 
for the condition under investigation. In patients with an ambiguous clinical diagnosis, it is 
often very difficult to establish whether a specific sequence variant is disease causing and 
usually requires careful clinical assessment of patients and their relatives. 
 
Therefore, to ensure accurate clinical diagnosis, provide optimal counselling and management 
of families with hereditary cardiovascular conditions it is essential that cardiologists, molecular 
biologists, bio-informaticians, and clinical geneticists, work closely together as a team, ideally 
in expert centres. This facilitates multidisciplinary case discussion and constant review of the 
indications for genetic testing, counselling strategies, and interpretation of sequencing results. 
By pooling the experience of such teams in public databases it will soon be possible to translate 
all the data generated by NGS into usable knowledge for the benefit of patients and their 
families. 
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 Table 1 
 
Summary of viewpoints on the use of next-generation sequencing in genetic diagnosis of 
hereditary cardiovascular conditions 
 
 Before genetic testing it is important to inform the patient about the challenges in 
interpretation of sequencing results of multiple genes and discuss the implications of 
unsolicited findings 
 
 In a clinical diagnostic setting only recognized disease genes should be investigated 
in patients fulfilling diagnostic criteria of a specific cardiovascular condition 
 
 Whole exome/genome sequencing is considered to be a diagnostic method in 
development and should be used for genetic diagnosis only if filtered against 
recognised disease genes. The coverage should allow identification of all exomic 
variants in these genes 
 
 Interpretation of sequencing results should take place in close collaboration between 
bio-informaticians, cardiologists, molecular biologists, clinical geneticists, 
preferably in expert centres 
 
 Development of public databases worldwide with clinical information and 
sequencing results are essential to ensure optimal patient management 
 
 Prospective re-evaluation of variants of uncertain significance is essential 
 
 Algorithms for re-contacting referring physicians and patients have to be developed 
 
 
 
 
